Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking. | Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealm…
Market Samachar is a news aggregator. This article was originally published by FiercePharma. Tap the button above to read the full story on their site.